Inclusion Criteria:

- Patients ≥18 years old, who must understand and voluntarily sign an Informed Consent.

- Patients must have documented diagnosis of Multiple Myeloma and have measurable
disease.

- Patients must have undergone prior treatment with ≥ 2 treatments lines, of
anti-myeloma therapy.

- Patients must have either refractory or relapsed and refractory disease.

- Patients must have received at least 2 consecutive cycles of prior treatment that
include lenalidomide and bortezomib, either alone or in combination regimens.

- Patients must have received adequate alkylator therapy

Exclusion Criteria:

- Prior history of malignancies, other than Multiple Myeloma.

- Previous therapy with Pomalidomide, hypersensitivity to thalidomide and lenalidomide
or dexamethasone.

- Patients who received an allogeneic bone marrow or allogeneic peripheral blood stem
cell transplant.

- Patients who are planning for or who are eligible for stem cell transplant.

- Patients who received major surgery and any anti-myeloma drug therapy within the last
14 days of starting study treatment.

- Patients with a current disease that can interfere with protocol procedures or study
treatment.

- Patients unable or unwilling to undergo antithrombotic prophylactic treatment.

- Pregnant or breastfeeding females.